Summit Therapeutics Share Discussion Threads

[waterloo01] 09/1/2018 14:48

It is and they have no vested interest. Suntrust note last week was also very positive. Webcast this afternoon. Sit tight IMO as we get to an inflection point this quarter!

[football] 09/1/2018 14:45

thanks waterloo01 thats a detail write up

[waterloo01] 09/1/2018 14:42

$44 target. Highest yet!

[luminoso] 08/1/2018 22:40

It keeps having a look at 12 dollars before sliding back.

[luminoso] 05/1/2018 16:58

I wonder if there is time for SUMM to be added to this conference, considering RID has performed as well against Vancomycin as Iclaprim ( if not better ) and the acquisition of Discuva.

[chrisatrdg] 05/1/2018 16:30

Companies participating at Biotech Showcase 2018 to date includes Summit:
January 8–10, 2018
HILTON SAN FRANCISCO UNION SQUARE,
San Francisco, CA 94102 USA



Edit:
Public Presentation

Summit Therapeutics plc
NASDAQ: SMMT
United Kingdom

Tue, January 9 at 4:00 pm
Hilton/Yosemite B, Level Ballroom Level

[luminoso] 05/1/2018 12:42

Daily mail covered this day before yesterday -

[football] 05/1/2018 08:44

From 19.03 programs run time

[euroto] 04/1/2018 20:54

Be aware folks that the share price data on the other BB is currently not accurate.

[luminoso] 04/1/2018 19:03

Thanks freedosh. Good to hear from you again. Hopefully there will be enough encouragement from the P2 EZT results, which will make the potential of the reformulations extremely mouth watering to our suitors.

[waterloo01] 04/1/2018 18:58

Good to see you post. Fingers crossed.

See we have new coverage from Suntrust with a $24.00 target.

[freedosh] 04/1/2018 16:40

Hi luminoso
Yes Rid is a valuable asset and, in my view, pretty much derisked. DMD though is our potential blockbuster whilst carrying some risk. We have second generation formulations in the pipeline so I consider the risk to relate only to the efficacy of utrophin upregulation vs DMD not our ability to achieve adequate utrophin upregulation.
Have a great New Year Summit and all here.

[luminoso] 04/1/2018 15:14

Thanks, chrisatrdg for your summary of the webcast. Really appreciate that. With the article on SRPT mentioning a possible buy out of Summit ( most likely only EZT ) it does confirm what I have been thinking for a few months now. DMD to be hived off and almost certainly sold to SRPT and a new anti microbial company goes forward. I have to acknowledge that freedosh was saying a long time ago that he saw the C.Diff drug as the future of Summit, when I and many others saw DMD as the be all and end all.
Fingers and everything else crossed for results this quarter and a good offer afterwards !

[chrisatrdg] 03/1/2018 20:04

Hi waterloo01 I think your brief summary sums up the position very well & I agree completely particularly on risk !!

[waterloo01] 03/1/2018 20:01

Thanks for the feedback. I suspect a mix of derisking and adding longer term value by having enough critical mass behind both streams, so that company both keeps going regardless of the next results but if DMD does work out, they could sell that and continue and build into a pure play antibiotic business.

I think the comment that roche are far from transparent also means they couldn't value the collaboration, hence why they don't pay for it upfront in the valuation but equally only share the rewards 50/50.

[chrisatrdg] 03/1/2018 19:50

I am not sure what to make of todays conference call but listening to the questions & answers from the 5 institutions I learnt as follows:

1) The answer given to J.P.Morgan as to 'cash back' from the deal suggests that Summit are yet to decide which aspects of Discuva's work they will go for so not yet able to say how things will work out plan wise.

2)In another answer from another institution on staffing etc in relation to the additional costs it was said there would be 10 staff being kept & the floor space was 7,000 to 8,000 square feet.By using the phrase staff being kept in the answer suggests that not all staff have stayed with Discuva.

3)In another answer from another institution question Roche deal was not the driver for the purchase & any income from it in my words would be a bonus.

In addition that because Roche was now going in house there was less income for Discuva who needed further funding for further development.It seems to me that the baton has been passed onto Summit avoiding need for further external funding.

In addition to other questions Glyn mentioned that the Company could be split, once the DMD results are known, into a DMD Company & a C-Diff/Discuva Company which I think would facilitate Buy outs to create investor appreciation.

In summary it seems to me that the cash benefits from the Discuva deal will not be known until Summit have decided the direction it will take Discuva's work.Having followed Discuva before the RNS, as I have said before, I have regarded it as being at the cutting edge of technology for the fight against anti-biotic resistance & now combined with Summit could make Summit a 'world class' leader in this field but true share holder appreciation would be a few years further down the line.

[chrisatrdg] 03/1/2018 19:09

Sarepta Therapeutics: 2017 Was A Double, 2018 Looks Promising As Well



It should be noted that there is mention of the suggestion that Serepta with its cash pile could Buy Summit in 2018.This for me is the first time I have seen mention of a Buy out of Summit & a good reason why Summit may wish to split out DMD out into a separate company likely to be US based to facilitate such a purchase.Goods times ahead we hope.

[makingmillions] 03/1/2018 18:34

Ct order on smmt adrs. What does that mean.?

[chrisatrdg] 03/1/2018 14:52

Below are ddubya's comments from the other board following Free - Money's comments relating to todays conference -

'That seems like a pretty concise summary FM. Not enough to move the share price upwards but positive long term and with the possibility of some income from the Roche/Discuva arrangements.

The only thing I would add is that the first DMD results are confirmed as on track for Q1 2018.

As an aside GE did say they were happy with their progress in creating value and also that DMD could be absolutely huge by the end of 2018. I would like to hope so but the latter comment at least should be taken with a pinch of salt until data is in. However, I would have thought it a most unwise statement to make in the absence of confidence in trials progress?'

[chrisatrdg] 03/1/2018 14:10

Below is Free- Moneys take on things from the other board:

'Listened in. Lots of new stuff to consider.

My initial thoughts are long term very exciting with possible discovery of new antibiotics to follow along the path of Summits own Ridnilazole development. Nothing new hitting the clinic this year though.

Short term increased costs of ten new employees and 70,000 square foot lab in Cambridge.

Depending on DMD results this year the company may split in two if the business models going forward are different enough.

In summary Summit is getting bigger and long term now has more options. GLA'

[chrisatrdg] 03/1/2018 14:08

Hi waterloo01 & all - I did post a few notes but it was lost when I updated but will get back latter this afternoon but for now I can say I do not see a surge in the share price until things are clearer with the acquisition benefits.

[waterloo01] 03/1/2018 13:47

Good stuff, although missed a chunk of it. Care to summerise Chrisatdrg?

Interesting, and probably obvious that depending on results that they might conclude to split the company into two (or sell one or both?). DMD results are this quarter as Glyn corrected himself at the end.

[chrisatrdg] 03/1/2018 11:22

Webcast registration now open for today:

[solomon] 01/1/2018 13:43

Goes without saying that the DM has quite some clout with PI's. The effect lasted for several days when AMYT was tipped (not enough to get me above water though).

[waterloo01] 01/1/2018 11:24

BUY THIS: Summit Therapeutics

Analysts at Panmure Gordon have recommended drugs development firm Summit Therapeutics as a ‘buy’ after it snapped up Cambridge rival Discuva for £10million.

Panmure Gordon reckons the purchase will broaden Summit’s expertise as it capitalises on Discuva’s technology and existing partnerships, including a research collaboration with Swiss multinational Roche.